Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context | Zendy

Antonio GonzálezMartín | Zendy; Ursula A. Matulonis | Zendy; Jacob Korach | Zendy; Mansoor Raza Mirza | Zendy; Kathleen N. Moore | Zendy; Xiaohua Wu | Zendy; Whitney York | Zendy; Divya Gupta | Zendy; Stanislav Lechpammer | Zendy; Bradley J. Monk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context

Author(s) -

Antonio GonzálezMartín,

Ursula A. Matulonis,

Jacob Korach,

Mansoor Raza Mirza,

Kathleen N. Moore,

Xiaohua Wu,

Whitney York,

Divya Gupta,

Stanislav Lechpammer,

Bradley J. Monk

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2022-0206

Subject(s) - medicine , oncology , ovarian cancer , context (archaeology) , brca mutation , adverse effect , biomarker , clinical trial , cancer , biology , biochemistry , paleontology

We reviewed clinical data for niraparib monotherapy in BRCA -mutated ( BRCA m) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCA m versus non- BRCA m cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCA m OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research